Major Adverse Cardiovascular Events (DBCOND0069054)
Identifiers
- Synonyms
- Major Adverse Cardiovascular Event
Associated Data
- Indicated Drugs and Targets
Drug Description Targets Dulaglutide A GLP-1 agonist used to manage type 2 diabetes mellitus.Liraglutide A GLP-1 analog used in the management of type 2 diabetes mellitus, prevention of cardiovascular complications associated with diabetes, and obesity.- Glucagon-like peptide 1 receptortarget
- Dipeptidyl peptidase 4enzyme
- Neprilysinenzyme
- Albumincarrier
Rivaroxaban A factor Xa inhibitor used to treat deep vein thrombosis (DVT) and pulmonary embolism (PE). May also be used as thrombosis prophylaxis in specific situations.- Coagulation factor Xtarget
- Cytochrome P450 3A4enzyme
- Cytochrome P450 2J2enzyme
- ATP-dependent translocase ABCB1transporter
- Cytochrome P450 3A5enzyme
- Broad substrate specificity ATP-binding cassette transporter ABCG2transporter
Rosuvastatin An HMG-CoA reductase inhibitor used to lower lipid levels and reduce the risk of cardiovascular disease including myocardial infarction and stroke.- 3-hydroxy-3-methylglutaryl-coenzyme A reductasetarget
- Cytochrome P450 2C9enzyme
- ATP-binding cassette sub-family C member 4transporter
- Solute carrier organic anion transporter family member 1A2transporter
- Solute carrier organic anion transporter family member 1B3transporter
- Solute carrier organic anion transporter family member 2B1transporter
- Cystine/glutamate transportertransporter
- Solute carrier organic anion transporter family member 1B1transporter
- Bile salt export pumptransporter
- Broad substrate specificity ATP-binding cassette transporter ABCG2transporter
- Albumincarrier
- ATP-binding cassette sub-family C member 2transporter
- Organic anion transporter 3transporter
- Hepatic sodium/bile acid cotransportertransporter
- Integrin alpha-Ltarget
Semaglutide A glucagon-like peptide 1 receptor agonist used to improve glycemic control in type 2 diabetes mellitus, treat obesity, and reduce the risk of major adverse cardiovascular events in selected adults.- Albumincarrier
- Dipeptidyl peptidase 4enzyme
- Neprilysinenzyme
- Glucagon-like peptide 1 receptortarget
- Lipoprotein lipaseenzyme
- Clinical Trials
Identifier Title Drug(s) Purpose Phase Status NCT04992195 Impact of COVID-19 Vaccines on Cerebrovascular Health No drug interventions Not Available Not Available recruiting NCT05578300 Effective Translation of Endovascular Thrombectomy Trials Into Real-world Practice in the Asia-Pacific No drug interventions Not Available Not Available recruiting NCT05378035 DOAC in Chinese Patients With Atrial Fibrillation No drug interventions Not Available Not Available recruiting NCT04691037 CCTA Improves Clinical Management of Stable Chest Pain No drug interventions Not Available Not Available recruiting NCT02072538 Pre-discharge vs. Early Post-discharge Stress Testing and GRACE Score for Safe Discharge of ACS-patients With a Negative Hs-troponin T Result No drug interventions Not Available Not Available withdrawn NCT02806102 CardiOvascular Risk and idEntificAtion of Potential High-risk Population in Acute Myocardial Infarction II (COREA-AMI II) No drug interventions Not Available Not Available unknown_status NCT03175952 Virtual Histology Intravascular Ultrasound to Evaluate Prognostic Risks of Saphenous Vein Graft Disease Before Percutaneous Coronary Intervention. No drug interventions Not Available Not Available unknown_status NCT06355219 Macrovascular and Microvascular Morbidity and Mortality After Metabolic Surgery Versus Medicines No drug interventions Not Available Not Available completed NCT04580017 Prognostic Accuracy of the HEART Score in Undifferentiated Chest Pain: A Multicenter Validation Study No drug interventions Not Available Not Available completed NCT03164226 Prognostic Value of Non-invasive Index of Endothelial Function. No drug interventions other Not Available completed NCT06318767 Predictive Value of Systolic Rise Time of the Plantar Arch on the Risk of Major Adverse Limb Events (MALE) and Major Adverse Cardiovascular Events (MACE) in Peripheral Artery Disease (PAD) at Critical Ischaemia Stage No drug interventions diagnostic Not Available recruiting NCT05623995 Effect of Evolocumab on Chronic Total Occlusions (EVOLO-CTO) treatment 4 recruiting